SWI Initiates Coverage on Hemispherx Biopharma, Inc.
Download Research Report - Watch CEO Interview
Marina del Rey, CA - August 11, 2016 - SWI today announced that it has initiated coverage on Hemispherx Biopharma, Inc. (NYSE:HEB).  HEB is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO. 
Debilitating diseases are a complex mosaic of an estimated 6,000 –8,000 conditions. The US demand for drug delivery products are expected to  expand 10.4 percent annually from $168 Billion in 2016 to $319 billion by 2021. HEB's product development aims to take advantage of this huge market opportunity.
HEB Research Report
Hemispherx is aggressively pursuing co-development and/or licensing partners for Ampligen® with focus on Immune-Oncology, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and vaccines. The company is also seeking co-development and/or licensing partners for Alferon  to expedite product development and revenue generation.
Watch CEO Interview on Small Cap Nation Here

Hemispherx Biopharma, Inc. is a company that has implemented a structure with promising products prone for extraordinary success in place. We consider HEB  an exceptional investment opportunity that you cannot afford to miss.
Creation of Stock Value Through the Advancement
of the Company's Lead Products
 S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.  SWI has been engaged by Small Cap Nation, an on-demand video news and information broadcasting platform and will be compensated in cash for the publication of the information herein. The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.